Synergy Pharmaceuticals Announces Positive Results in the First Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Synergy (SGYP) PT Lifted to $19 at Canaccord Genuity; 'This Thang Don't Stank'
June 18, 2015 9:50 AM EDTCanaccord Genuity analyst Corey Davis reiterated a Buy rating and boosted his price target on Synergy Pharmaceuticals (NASDAQ: SGYP) to $19.00 (from $11.00) in a note entitled "This thang don't stank." The price target hikes follows "best positive top-line results we could have hoped for from the first of its two Phase 3 trials for plecanatide in chronic idiopathic constipation (CIC)."
Both doses, 3.0mg and... More
Synergy (SGYP) Seen as Attractive Takeout Target at Cantor Fitzgerald; PT Up to $14
June 17, 2015 11:38 AM EDTCantor Fitzgerald analyst Irina Rivkind Koffler reiterated a Buy rating and boosted her price target on Synergy Pharmaceuticals (NASDAQ: SGYP) to $14.00 (from $8.50) following unexpectedly strong Phase III data.
"We view Synergy as an attractive takeout target following its positive Phase III data in... More
Synergy Pharma's (SGYP) Phase 3 Trial of Plecanatide in Patients with CIC Mets Primary Endpoint
June 17, 2015 6:37 AM EDTSynergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in 1,346 adult patients with chronic idiopathic... More
